Hemorrhagic cystitis: a retrospective single‐center survey

Hassan, Zuzana; Remberger, Mats; Svenberg, Petter; Elbander, Maria; Omazic, Brigitta; Mattsson, Jonas; Conrad, Réka; Svahn, Britt-Marie; Ahlgren, Anders; Sairafi, Darius; Aschan, J; Blanc, Katarina Le; Barkholt, Lisbeth; Ringdén, Olle

doi:10.1111/j.1399-0012.2007.00705.x

Cited by 58 publications

(73 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Demographic risk features include male sex (Asano et al, 2003;Hale et al, 2003) and age >10 years (Kondo et al, 1998;Seber et al, 1999;Cesaro et al, 2003;Cheuk et al, 2007). GvHD is a consistent risk factor in paediatric (Russell et al, 1994;Hale et al, 2003;Cheuk et al, 2007) mixed (Seber et al, 1999;El-Zimaity et al, 2004;Hassan et al, 2007) and adult (Chakrabarti et al, 2003) study cohorts. Busulphan (Kondo et al, 1998;Trotman et al, 1999) and cyclophosphamide conditioning (Brugieres et al, 1989;Cheuk et al, 2007), important risk factors for pre-engraftment HC, also seem to increase risk of post-engraftment HC.…”

Section: Diagnosis and Risk Factors For Bkv Infection In Hsctmentioning

confidence: 99%

Prevention and management of BK‐virus associated haemorrhagic cystitis in children following haematopoietic stem cell transplantation – a systematic review and evidence‐based guidance for clinical management

et al. 2008

View full text Add to dashboard Cite

SummaryHaemorrhagic cystitis (HC) is a common and, in its severe form, potentially life-threatening complication of Haematopoietic stem cell transplantation (HSCT) in children. Recent data indicate an important role of BK virus reactivation during the time of maximal post-transplant immune suppression in the pathogenesis of late-onset HC. Treatment of HC is mainly symptomatic and often frustrating. To give clinicians guidance on prevention and treatment options and their backing by scientific evidence, we have systematically assessed the available literature and devised evidence-based guidelines. Our comprehensive review demonstrates that evidence for the most commonly used interventions (such as cidofovir, oestrogen, hyperbaric oxygen, bladder instillation with formalin, alum salts or prostaglandin) is very limited. Some of these interventions also carry significant risks. Higher level evidence exists only for 2-mercaptoethane sodium (MESNA) and hyperhydration as a preventative intervention, and for systemic recombinant Factor VII as a treatment to stop acute haemorrhage. Further high-quality studies are required to establish effective and safe prevention and treatment options for HC.

show abstract

Section: Diagnosis and Risk Factors For Bkv Infection In Hsctmentioning

confidence: 99%

Prevention and management of BK‐virus associated haemorrhagic cystitis in children following haematopoietic stem cell transplantation – a systematic review and evidence‐based guidance for clinical management

et al. 2008

View full text Add to dashboard Cite

show abstract

“…15 The definition of hemorrhagic cystitis was used as follows: painful hematuria with a negative urine culture for bacteria or fungus and without any other explanation such as general bleeding diathesis, urinary tract catheterization for reasons other than hemorrhagic cystitis, urinary calculi or bladder neoplasms. 16 The study was approved by Hacettepe University Ethical Committee according to the 'Declaration of Helsinki'.…”

Section: Patientsmentioning

confidence: 99%

Evaluation of oxidative and antioxidative parameters in pediatric hematopoietic SCT patients

Sabuncuoğlu

Kuşkonmaz

Çetinkaya

et al. 2011

Bone Marrow Transplant

View full text Add to dashboard Cite

Conditioning regimens preceding hematopoietic SCT (HSCT) usually consist of high-dose chemotherapy. Chemotherapy and radiation therapy are associated with increased formation of free radicals and depletion of critical plasma and tissue antioxidants. Oxidative stress and antioxidant depletion have been described during the transplantation period in HSCT patients. In a limited number of studies, it was observed that the conditioning regimen resulted in oxidative stress and antioxidant depletion in HSCT patients. The objective of this study was to look for further evidence of oxidative stress and antioxidant status in pediatric HSCT patients. In this study, blood samples were collected from 21 pediatric allo-HSCT patients before and after conditioning therapy. Erythrocyte and plasma malondialdehyde (MDA) levels, erythrocyte reduced and oxidized glutathione (GSH) levels, erythrocyte antioxidant enzymes activities, plasma a-tocopherol and b-carotene levels were determined. After high-dose chemotherapy, erythrocyte and plasma MDA levels increased. Reduced GSH levels decreased whereas oxidized GSH levels increased first and then decreased significantly compared with the values before the chemotherapy regimen. It was also observed that catalase, superoxide dismutase and GSH-S-transferase activities decreased, but there was no change in GSH peroxidase activity. On the other hand, plasma a-tocopherol levels increased, but b-carotene levels did not change.

show abstract

“…Hemorrhagic cystitis (HC) may occur after HSCT either as early-onset disease due to conditioning toxicity, or late-onset disease associated with GVHD or viral infections such as BK virus, adenovirus, and cytomegalovirus (CMV) [4,5,6,7,8,9]. The incidence of HC after HSCT has been reported to range from 10 to 70%.…”

Section: Introductionmentioning

confidence: 99%

Placenta-Derived Decidua Stromal Cells for Hemorrhagic Cystitis after Stem Cell Transplantation

Aronsson-Kurttila

Baygan²,

Moretti³

et al. 2018

Acta Haematol

Self Cite

View full text Add to dashboard Cite

Background/Aims: Hemorrhagic cystitis (HC) is a serious complication after hematopoietic stem cell transplantation (HSCT). Stromal cells have been tested as therapy for HC. Decidua stromal cells (DSCs) protect the fetus from the mother's immune system. Methods: Eleven patients with HC of grades 3-4 were treated with DSCs after HSCT. The median age was 33 years (range 8-50), and the median dose of DSCs was 1.5 × 10⁶/kg (range 0.7-2.5). The patients were given 1 dose (1-4). Results: In 5 patients, HC disappeared within 5 days after DSC infusion. Patients who received DSCs within 3 days after the start of HC had a duration of HC of 5 days and a shorter duration of pain than patients who were given DSCs later (p = 0.02). Three patients received DSCs prepared in albumin instead of AB-plasma and tended to have a shorter duration of pain (p = 0.07). There was no infusion toxicity. Adverse events were those often seen after HSCT. Nine of the 11 patients (82%) were alive 1 year after HSCT. Conclusions: Based on this pilot study, we started a randomized, placebo-controlled double-blind study using 2 doses of 1 × 10⁶ DSCs/kg suspended in albumin for treatment of early HC.

show abstract

Hemorrhagic cystitis: a retrospective single‐center survey

Cited by 58 publications

References 38 publications

Prevention and management of BK‐virus associated haemorrhagic cystitis in children following haematopoietic stem cell transplantation – a systematic review and evidence‐based guidance for clinical management

Prevention and management of BK‐virus associated haemorrhagic cystitis in children following haematopoietic stem cell transplantation – a systematic review and evidence‐based guidance for clinical management

Evaluation of oxidative and antioxidative parameters in pediatric hematopoietic SCT patients

Placenta-Derived Decidua Stromal Cells for Hemorrhagic Cystitis after Stem Cell Transplantation

Contact Info

Product

Resources

About